These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 21766430)

  • 41. Isotretinoin exposure and pregnancy outcome: an observational study of the Berlin Institute for Clinical Teratology and Drug Risk Assessment in Pregnancy.
    Schaefer C; Meister R; Weber-Schoendorfer C
    Arch Gynecol Obstet; 2010 Feb; 281(2):221-7. PubMed ID: 19444462
    [TBL] [Abstract][Full Text] [Related]  

  • 42. A study of the potential teratogenic effects of large doses of drugs rarely used for a suicide attempt during pregnancy.
    Timmermann G; Acs N; Bánhidy F; Czeizel AE
    Toxicol Ind Health; 2008; 24(1-2):121-31. PubMed ID: 18818188
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Linking a pharmaceutical claims database with a birth defects registry to investigate birth defect rates of suspected teratogens.
    Colvin L; Slack-Smith L; Stanley FJ; Bower C
    Pharmacoepidemiol Drug Saf; 2010 Nov; 19(11):1137-50. PubMed ID: 20602344
    [TBL] [Abstract][Full Text] [Related]  

  • 44. The neurobehavioral teratology of retinoids: a 50-year history.
    Adams J
    Birth Defects Res A Clin Mol Teratol; 2010 Oct; 88(10):895-905. PubMed ID: 20865785
    [TBL] [Abstract][Full Text] [Related]  

  • 45. The CTIS Womb to Classroom Screening Program for the detection of agents with adverse effects on neuropsychological development.
    Adams J; Janulewicz PA; Kao K; Jones KL; Chambers C
    Birth Defects Res A Clin Mol Teratol; 2012 Jun; 94(6):486-93. PubMed ID: 22522347
    [TBL] [Abstract][Full Text] [Related]  

  • 46. [Antipsychotic agents and pregnant women. A case report].
    Handal M; Matheson I; Bechensteen AG; Lindemann R
    Tidsskr Nor Laegeforen; 1995 Aug; 115(20):2539-40. PubMed ID: 7676418
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Teratogen update: evaluation of the reproductive and developmental risks of caffeine.
    Christian MS; Brent RL
    Teratology; 2001 Jul; 64(1):51-78. PubMed ID: 11410911
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Use of cephalosporins during pregnancy and in the presence of congenital abnormalities: a population-based, case-control study.
    Czeizel AE; Rockenbauer M; Sørensen HT; Olsen J
    Am J Obstet Gynecol; 2001 May; 184(6):1289-96. PubMed ID: 11349204
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The way women perceive teratogenic risk.
    Koren G
    Can J Clin Pharmacol; 2007; 14(1):e10-6. PubMed ID: 17213504
    [No Abstract]   [Full Text] [Related]  

  • 50. Pregnancy outcome after prenatal quinolone exposure. Evaluation of a case registry of the European Network of Teratology Information Services (ENTIS).
    Schaefer C; Amoura-Elefant E; Vial T; Ornoy A; Garbis H; Robert E; Rodriguez-Pinilla E; Pexieder T; Prapas N; Merlob P
    Eur J Obstet Gynecol Reprod Biol; 1996 Nov; 69(2):83-9. PubMed ID: 8902438
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Evaluation of drug intake during pregnancy in the Hungarian Case-Control Surveillance of Congenital Anomalies.
    Czeizel A; Rácz J
    Teratology; 1990 Nov; 42(5):505-12. PubMed ID: 2148987
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Pregnancy outcome after exposure to ranitidine and other H2-blockers. A collaborative study of the European Network of Teratology Information Services.
    Garbis H; Elefant E; Diav-Citrin O; Mastroiacovo P; Schaefer C; Vial T; Clementi M; Valti E; McElhatton P; Smorlesi C; Rodriguez EP; Robert-Gnansia E; Merlob P; Peiker G; Pexieder T; Schueler L; Ritvanen A; Mathieu-Nolf M
    Reprod Toxicol; 2005; 19(4):453-8. PubMed ID: 15749258
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Teratology, 40 years after the thalidomide tragedy].
    Burdan F
    Ginekol Pol; 2001 Feb; 72(2):93-100. PubMed ID: 11387997
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Principles and practice of teratology for the obstetrician.
    Fisher B; Rose NC; Carey JC
    Clin Obstet Gynecol; 2008 Mar; 51(1):106-18. PubMed ID: 18303504
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prenatal exposure to sex hormones: a case-control study.
    Martínez-Frías ML; Rodríguez-Pinilla E; Bermejo E; Prieto L
    Teratology; 1998 Jan; 57(1):8-12. PubMed ID: 9516746
    [TBL] [Abstract][Full Text] [Related]  

  • 56. [The local and general teratogenic effects of soft and hard drugs on the neonate].
    Mirra M
    Arch Stomatol (Napoli); 1988 Nov; 29(5):1127-40. PubMed ID: 3272569
    [No Abstract]   [Full Text] [Related]  

  • 57. Identifying associations between maternal medication use and birth defects using a case-population approach: an exploratory study on signal detection.
    de Jonge L; Zetstra-van der Woude PA; Bos HJ; de Jong-van den Berg LT; Bakker MK
    Drug Saf; 2013 Nov; 36(11):1069-78. PubMed ID: 23828658
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Risk of drug-induced congenital defects.
    De Santis M; Straface G; Carducci B; Cavaliere AF; De Santis L; Lucchese A; Merola AM; Caruso A
    Eur J Obstet Gynecol Reprod Biol; 2004 Nov; 117(1):10-9. PubMed ID: 15474237
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Teratogens during pregnancy].
    Jancárková N; Gregor V
    Ceska Gynekol; 2000 May; 65(3):188-94. PubMed ID: 10953498
    [TBL] [Abstract][Full Text] [Related]  

  • 60. A study of the teratogenic and fetotoxic effects of large doses of barbital, hexobarbital and butobarbital used for suicide attempts by pregnant women.
    Timmermann G; Czeizel AE; Bánhidy F; Acs N
    Toxicol Ind Health; 2008; 24(1-2):109-19. PubMed ID: 18818187
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.